U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07474285) titled 'Cenobamate Efficacy in Individuals With Autoimmune Epilepsy' on March 11.
Brief Summary: Over the last decades, multiple neuronal autoantibodies directed against intracellular or cell-surface antigens have been identified in association with epilepsy and encephalopathy. In some patients with immune-mediated brain disorders, seizures persist and become chronic despite treatment with antiseizure medications (ASMs) and immunotherapy. This condition is particularly common in patients with antibodies against glutamic acid decarboxylase 65 (GAD65) or onconeural antigens (e.g., Hu, Ma2, and CRMP5/CV2). The persistence of seizures despite ...